Roche H1N1 flu test wins emergency clearance
This article was originally published in The Gray Sheet
Executive Summary
FDA grants emergency use authorization to Roche's RealTime Ready Influenza A/H1N1 Detection Set,which will allow clinicians to test for the presence of the 2009 H1N1 influenza virus collected via nasopharyngeal swabs, nasal swabs, washes and aspirates in clinical settings, and "augment existing testing capacity" for the H1N1 virus, FDA says in its Nov. 13 EUA letter. FDA has also granted emergency use authorization for use of Roche's Detection Set on the company's LightCycler 2.0 ("1The Gray Sheet" Aug. 24, 2009)
You may also be interested in...
Feds Seeking A Few Good Tests, And Masks, For Flu Season
With an especially challenging flu season expected this year, government officials are scrambling to evaluate the tools they have available to monitor, diagnose and limit spread of the virus
As Casgevy, Lyfgenia Launches Proceed, CRISPR And bluebird bio CEOs Reassure
The CEOs of bluebird bio and CRISPR Therapeutics hope to inspire investor confidence that their gene-based therapies for sickle cell disease and beta thalassemia will be widely reimbursed in the US and EU.
Japan Regulatory Update: Revised Law Widens RWD Scope, Price Revisions/Listings
Japan now allows pseudonymized personal data for medical use under a licensing system for wider use of real-world data. Meanwhile, a national cost-effectiveness assessment scheme has slashed reimbursement prices for Lagevrio and Kerendia, and Alexion’s Voydeya has been added to the reimbursement tariff.